Press Release

Therapeutic Plasma Exchange Market to Grow with a CAGR of 6.75% through 2028

Advances in therapeutic plasma exchange research & development and expanding variety of therapeutic plasma exchange applications is expected to drive the Global Therapeutic Plasma Exchange Market growth in the forecast period, 2024-2028.

According to TechSci Research report, Therapeutic Plasma Exchange Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F Global Therapeutic Plasma Exchange Market stood at USD 762.01 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.75% through 2028. The expansion of the Therapeutic Plasma Exchange Market can be attributed to advancements in research and development, an increased prevalence of neurological, renal, and hematological disorders, and a growing range of therapeutic plasma exchange applications. The rise in global R&D activities is propelling the market forward, along with its extensive medical applications. Factors contributing to market growth include the rising number of clients with inflammatory illnesses, hematological disorders, cardiovascular diseases, and the elderly population. Neurological health issues have significantly increased among the elderly, and the use of cutting-edge techniques like plasma exchange for treating neurological illnesses is gaining recognition. These elements are expected to create significant demand opportunities in the global therapeutic plasma exchange market.

Applications in the treatment of various neurological illnesses are a major growth driver for the Global Therapeutic Plasma Exchange Market. Therapeutic Plasma Exchange (TPE) is accepted as a first-line therapy, either as a stand-alone or in conjunction with other therapies, for neurological diseases such as acute inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Continuous technological advancements have led to significant improvements in high-precision methods. This has resulted in enhanced patient satisfaction and more efficient processing of blood and plasma products. In comparison to other technologies such as membrane separation methods, this particular method requires a minimal amount of blood flow. It represents a more advanced technique that simplifies the process of obtaining blood through the patient's antecubital or radial veins. Furthermore, these technological advancements have also enabled more precise control of hydration status, leading to greater hemodynamic stability during treatment. Ultimately, these advancements contribute to improved patient comfort, safety, and efficacy in TPE operations, creating promising opportunities in the market.

The therapeutic plasma market is experiencing rapid growth due to the increasing prevalence of chronic conditions worldwide. Moreover, advancements in medical device technology are driving widespread adoption in hospitals and clinical settings. The growing preference for therapeutic plasma exchange systems in the treatment of various chronic conditions is fueling market expansion in both developed and developing countries. Many manufacturing companies are prioritizing the launch of cost-effective therapeutic plasma exchange systems to meet the strong demand from emerging markets.

TPE is also used as second-line therapy for other neurological diseases, including acute disseminated encephalomyelitis, chronic focal encephalitis, Lambert-Eaton myasthenic syndrome, Sydenham’s chorea, natalizumab-associated progressive multifocal leukoencephalopathy, multiple sclerosis, and neuromyelitis Optica (NMO, or Devic’s disease), often in combination with other treatments. The increasing price of apheresis equipment and disposables adds to the overall expense of apheresis. However, the expanding use of therapeutic plasma transfer for the treatment of various disorders provides potential growth prospects for market participants in the future. Therapeutic plasma exchange (TPE) is employed for treating neurological, hematological, renal, and autoimmune conditions with an immunological etiology. While therapeutic plasma exchange procedures are infrequently used in pediatric patients, the increasing number of clinical trials conducted globally is likely to further expand the market.

The cost of equipment significantly impacts the adoption of plasma exchange among medical professionals and, in turn, patients. Apheresis equipment is employed by blood banks for blood component collection, while hospitals utilize it for therapeutic plasma exchange procedures. The overall cost of apheresis treatments is further elevated by the expensive equipment and disposable items.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Therapeutic Plasma Exchange Market

The Global Therapeutic Plasma Exchange Market is segmented into product, technology, indication, end user, regional distribution, and company.

Based on indication, the market is segmented into neurological disorders, hematology disorders, renal disorders, metabolic disorders, and others. The Neurological disorders segment is projected to generate the highest revenue during the forecast period. This is attributed to the growing demand for their proven efficacy in managing neurological conditions such as Guillain-Barre syndrome (GBS), multiple sclerosis, and myasthenia gravis. In contrast, the cardiovascular disorders segment is expected to experience the highest growth rate, driven by the increased adoption of TPE as the primary treatment for various disorders like arteriosclerosis and rheumatic endocarditis. Moreover, technological advancements in this segment, expanding the applications of TPE in the removal of lipoproteins, fibrinogen, inflammatory factors, etc., are expected to fuel its growth throughout the forecast period.

Based on region, North America segment is expected to grow during the forecast period. North America is projected to maintain its dominant position in the therapeutic plasma exchange systems market throughout the forecast period. This dominance can be attributed to the global increase in the prevalence of autoimmune disorders, as well as the growing adoption of lipoprotein apheresis treatment for cardiovascular conditions such as CAD, hypercholesterolemia, strokes, and atherosclerosis, which have witnessed a rise in cardiac fatalities in recent years. For instance, according to The American Heart Association, in 2018, there were approximately 92.1 million individuals in the U.S. affected by cardiovascular diseases, resulting in a higher demand for TPE and driving market growth in the region. Furthermore, the availability of advanced technology and well-established healthcare infrastructures in North America are expected to contribute to the market's expansion throughout the forecast period.

Major companies operating in Global Therapeutic Plasma Exchange Market are:

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The rise in the prevalence of chronic diseases, along with the increased applications of therapeutic plasma exchange, has led to intensive research and clinical trials to determine its efficacy compared to other treatments. These factors are expected to drive market growth during the forecast period. The myriad uses of therapeutic plasma exchange in treating neurological, renal, hematological, and metabolic disorders will further propel the industry in the coming years. Moreover, therapeutic plasma exchange has proven to be an effective first-line treatment for certain neurological conditions. This is predicted to significantly enhance the market earnings in the future. Additionally, the increase in research and development activities globally is anticipated to stimulate a massive demand for therapeutic plasma exchange, resulting in substantial expansion of the business in the next decade. Furthermore, the rise in the number of patients with autoimmune ailments due to favorable reimbursement policies and healthcare consolidation will drive market growth. The extensive use of plasma exchange to effectively manage severe attacks of multiple sclerosis and Guillain-Barre syndrome, as well as other neurological disorders, will continue to fuel the growth and scope of the therapeutic plasma exchange market.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Therapeutic Plasma Exchange Market Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Consumables, Devices), By Technology (Centrifugation, Membrane Separation), By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others), By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others), By Region and Competition”, has evaluated the future growth potential of Global Therapeutic Plasma Exchange Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Therapeutic Plasma Exchange Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News